Abstract：
Adipose stromal vascular fraction (SVF) has a versatile cellular system for biologically augmented therapies. However, there have been no clinical studies investigating the benefits of the augmentation of anterior cruciate ligament reconstruction (ACLR) with SVF. We conducted a retrospective study in assessing the effects of intraoperative SVF administration on the functional outcomes in young patients with ACLR. The enrolled patients were divided into the control group (ACLR only) and the SVF group (ACLR with SVF). The functional outcomes in both groups were assessed by the Lysholm knee scoring system, the Tegner activity scale, and the International Knee Documentation Committee (IKDC) subjective evaluation form, and compared at several time points during a 12-month follow-up. We found that the sex distribution and pre-surgery scores were similar in the two groups, whereas the mean age of the SVF group was higher than that of the control group (p = 0.046). The between-group analysis and generalized estimating equation model analysis revealed that, while patients in the SVF group significantly improved all their functional outcomes at 12 months after surgery, this improvement was not significantly different from the results of patients in the control group (Lysholm, p = 0.553; Tegner, p = 0.197; IKDC, p = 0.486). No side effects were observed in either group. We concluded that the intraoperative administration of SVF does not improve or accelerate functional recovery after ACLR in young patients.
摘要：
脂肪基质血管部分（SVF）具有用于生物增强疗法的通用细胞系统。然而,目前还没有临床研究探讨SVF增强前交叉韧带重建术(ACLR)的益处.我们进行了一项回顾性研究，以评估术中SVF给药对年轻ACLR患者功能预后的影响。将入选患者分为对照组（仅ACLR）和SVF组（ACLR伴SVF）。通过Lysholm膝关节评分系统评估两组的功能结果，Tegner活动量表,和国际膝关节文献委员会(IKDC)主观评估表，并在12个月随访期间的几个时间点进行比较。我们发现两组的性别分布和术前评分相似,而SVF组的平均年龄高于对照组（p=0.046）。组间分析和广义估计方程模型分析表明，而SVF组的患者在术后12个月时显著改善了所有的功能结果，这种改善与对照组患者的结果没有显着差异(Lysholm，p=0.553;Tegner,p=0.197;IKDC,p=0.486)。两组均未观察到副作用。我们得出的结论是，术中给予SVF并不能改善或加速年轻患者ACLR后的功能恢复。
